Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 20Recruiting 13Active not recruiting 10Terminated 7Withdrawn 4Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × CPX-351 × Clear all
NCT05801835 2023-09-21

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase NA Unknown
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02272478 2020-01-23

AML18

Cardiff University

Phase 2/3 Unknown
1,600 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡